Ascendis Pharma announced that the online portal is now open for physicians wanting to request access to TransCon PTH, the Company’s investigational parathyroid hormone replacement therapy, through the U.S. Expanded Access Program. To qualify, patients must be adults diagnosed with hypoparathyroidism who live in the U.S., have prior PTH treatment experience, and meet other criteria outlined below and in the full treatment protocol. "We are pleased to have worked with the FDA to make TransCon PTH available for eligible patients in the U.S.," said Edward Trott, M.D., Vice President, Global Medical Affairs at Ascendis Pharma. "Recognizing the needs expressed by the hypopara community, we will continue to work with the FDA and others to make TransCon PTH, if approved, more broadly available as quickly as possible."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ASND:
- Ascendis Pharma price target raised to $177 from $169 at Wells Fargo
- Ascendis Pharma to initiate TransCon PTH U.S. expanded access program
- Ascendis Pharma to Initiate TransCon™ PTH U.S. Expanded Access Program for Adult Patients with Hypoparathyroidism
- Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference
- Ascendis Pharma’s Growth Hormone Shows Promising Results in China